A Novel Loss of Function Variant of SLC19A1 Presented with Immunodeficiency and Benefited from Folinic Acid Treatment

doi:10.21203/rs.3.rs-1866280/v2

Download PDF

Article

A Novel Loss of Function Variant of SLC19A1 Presented with Immunodeficiency and Benefited from Folinic Acid Treatment

https://doi.org/10.21203/rs.3.rs-1866280/v2

This work is licensed under a CC BY 4.0 License

Journal Publication

published 15 Dec, 2022

Read the published version in Genes & Immunity →

You are reading this latest preprint version

Insufficient dietary folate intake, hereditary malabsorption, or defects in folate metabolism may lead to combined immunodeficiency (CID). Although loss of function mutations in the major intestinal folate transporter PCFT/SLC46A1 was shown to be associated with CID, the evidence for pathogenic variants of RFC/SLC19A1 resulting in immunodeficiency was lacking. We report two cousins carrying a homozygous pathogenic variant c.1042G>A, resulting in p.G348R substitution who showed symptoms of immunodeficiency associated with defects of folate metabolism. SLC19A1 expression by peripheral blood mononuclear cells (PBMC) was quantified by real-time qPCR and immunostaining. T cell proliferation, methotrexate resistance, NK cell cytotoxicity, Treg cells and cytokine production by T cells were examined by flow cytometric assays. Patients were treated with and benefited from folinic acid (FA). Studies revealed normal NK cell cytotoxicity, Treg cell counts, and naive-memory T cell percentages. Although SLC19A1 mRNA and protein expression were unaltered, remarkably, mitogen induced-T cell proliferation was significantly reduced at sub- and supraoptimal folic acid concentrations. In addition, patients’ PBMCs were resistant to methotrexate-induced apoptosis supporting a functionally defective SLC19A1.

This study presents the second pathogenic SLC19A1 variant in the literature, providing the first experimental evidence that loss of function mutations in SLC19A1 may present with symptoms of immunodeficiency.

Folate

Immunodeficiency

SLC19A1

Reduced Folate Carrier

Folates play a critical role in both DNA and RNA synthesis in cells [1–6]. Insufficient dietary intake of folates or intestinal absorption, or defective folate metabolism disrupt purine and pyrimidine nucleotide synthesis, especially for rapidly proliferating tissues such as hematopoietic and immune systems [7, 8]. Folate derivatives are anionic in physiological pH and require predominantly active transporters to pass through cell membranes [9, 10]. The body's important membrane folate transporters are proton-coupled folate transporter (PCFT-SLC46A1) and reduced folate carrier (RFC-SLC19A1) [11–14]. PCFT expression is restricted to the duodenum and jejunum, liver, thus enabling folates to be absorbed from the intestine [10, 11]. Loss of function (LOF) mutations in the SLC46A1 gene have been reported to decrease folate reabsorption from the intestinal lumen leading to a condition called hereditary folate malabsorption (HFM) [10, 11]. Hematological and neurological symptoms are frequently observed in HFM, and the patients suffer from combined immunodeficiency [10–18].

RFC, encoded by the SLC19A1 gene, however, is ubiquitously expressed and is the main folate transporter in the mammalian cells and tissues [1, 12]. LOF mutations in SLC19A1 disrupt the entry of folate derivatives as well as antifolates (methotrexate (MTX) etc.) into the cells [1, 10, 14]. In Leiden Open Variation Database (LOVD), ~ 57 unique variants of SLC19A1 have been identified, almost all are polymorphisms and have been associated with drug resistance, neurological disorders, and cardiovascular diseases. In cancer treatment, antifolates such as MTX, which are structurally similar to folates, use the same membrane carriers (specifically RFC) [17, 18]. Polymorphisms in the SLC19A1 are the most important cause of drug resistance or excessively increased toxicity in cancer treatment [17, 18].

To this date, only one case of LOF mutation in SLC19A1 gene has been reported with severe megaloblastic anemia [19]. In addition, unlike the SLC46A1, the SLC19A1 was not associated with immunodeficiency before in the literature [20]. In the current report, we describe a second novel pathogenic variant of SLC19A1 with G348R substitution and provide evidence that the variant leads to a loss of function and impairs T cell proliferation response in reduced folate conditions, and thus may lead to immunodeficiency that could be alleviated with folic acid supplementation.

See detailed Supplemental Methods.

Case History of Patient 1

The patient was born at the 40th week of pregnancy and was hospitalized for 15 days due to respiratory distress. The patient was treated with intravenous antibiotics for one week due to lower respiratory tract infection (LRTI), bleeding in the mouth, and mucositis (Fig. 1a). Cytopenia, high triglyceride, low fibrinogen, and high ferritin levels were found. The patient had a sibling who died due to an uncontrolled pneumonia infection at 3.5 months of age (Fig. 1b). The patient was referred to our hospital for metabolic disease and immunodeficiency. Physical examination revealed fever (38.2°C), height < 10p, weight < 10p, head circumference < 10p, bleeding aphthous ulcers in the mouth, 2*1 cm swelling in the right sternocleidomastoid muscle associated. The liver and spleen were palpable below the costal margin 2 and 3 cm, respectively. Laboratory revealed WBC: 4.48x10³/mm³, Hb: 8gr/dl, Plt: 37x10³/mm³, MCV: 86.2 fl, Neu: 1.03x10³/mm3, Lym: 3.13x10³/mm³. AST: 38 U/L, ALT: 21 U/L, Triglyceride: 194 mg/dl, fibrinogen: 135 mg/dl, ferritin: 849 ng/ml, vitamin B12: 1095 pg/ml, folate: 11.4 ng/ml. The patient's immunological tests revealed slightly lower than the normal range (Table 1). Hemophagocytic lymphohistiocytosis was considered. Megaloblastic changes were observed in the bone marrow aspiration smear. Ceftriaxone (80 mg/kg/day) was started and 1 gr/kg/day IVIG was given for 2 days. Whole-exome sequencing (WES) was performed to assess the underlying genetic defect. CMV PCR test resulted in 2349 copies/ml, ganciclovir was initiated. CMV PCR was negative at the 2nd week of treatment. IgG level was as low as 200mg/dl before the IVIG. In WES, a homozygous variant (c.1042G > A) in the SLC19A1 gene, and a homozygous variant (c.*353dupAA) in ELK4 gene were reported. The patient's clinical and laboratory results were consistent with the defect in the SLC19A1. The patient’s symptoms ameliorated, and hematological and immunological tests normalized in the 2nd month of the folinic acid supplementation (Table 1). In the 2nd year of the treatment, neuromotor development is normal, and mouth sores and severe infections do not occur anymore (Fig. 1a). Upon his successful treatment, patient 1’s cousin (Patient 2) sought treatment presenting with neurological and immunological complaints. The detailed history of patient 2 is given in Supplemental Methods. The sores of patient 2 are shown in (Fig. 1a), and hematological and immunological tests are given in (Table 2), whose WES results eventually returned the same mutation in SLC19A1. Both patients’ mutations were confirmed by Sanger sequencing (Fig. S1).

Table 1

Summary of the clinical and laboratory results of patient 1
Period (age)	CBC					Lymphocyte subgroups						Immunoglobulins (Ig)
Period (age)	WBC X10³/mm³	Hb gr/dl	Plt X10³/mm³	MCV fl	Neu X10³/mm³	Lym X10³/mm³	CD3 % ( #)	CD4 % ( #)	CD8 % ( #)	CD 16 + 56 % ( #)	CD19 % ( #)	IgA (mg/dl)	IgM (mg/dl)	IgG (mg/dl)
Ti^lo-Ti^up (40 d-6 mo)						2416–9694	1492–6385	909–4523	254–2123	101–1633	237–2564	13–72	33–154	294–1165
(40 days, in diagnosis)	4.48	8	37	86.2	1.03	3.13	77.8 (2435)	57.4 (1796)	20.3 (635)	10.6 (331)	9.2 (287)	40	55	1053 (IVIG)
(2 months)	6.92	7.2	27	95.7	4.5	1.9	79.9 (1518)	53.7 (1020)	24 (456)	8.7 (165)	11.2 (212)	16	33	218
2nd month of treatment	16.22	12.1	411	77	3.39	11	45.3 (4983)	23.3 (2563)	19.4 (2134)	31.2 (3432)	21.9 (2409)	27.4	64	574
Ti^lo-Ti^up (1–2 y)						1829–10242	1338–6611	820–4138	540–2812	101–1741	516–3083	30–107	66–228	605–1430
8th month of treatment	16.86	13.7	457	74	2.95	12.3	58.5 (7195)	31.7 (3899)	22.8 (2804)	22.9 (2.816)	18.4 (2.263)	34.4	78.2	735
10st month of treatment	10.75	12	405	71.7	3.84	5.51	59.4 (3272)	36.9 (2033)	19 (1046)	10.2 (562)	30.4 (1675)	29.4	35.4	685
12th month of treatment	16.53	12.4	272	73.6	6.02	8.57	61.2 (5220)	29.9 (2570)	26.1 (2.228)	12.9 (1114)	25.8 (2211)	44.3	86.1	1004
18th month of treatment	12.29	12.8	360	73.5	3.87	6.830	61.4 (4190)	30.6 (2089)	27.4 (1870)	12.9 (881)	25.4 (1734)	38	46.6	798
24th month of treatment	16.5	12.5	440	75.6	6.78	7.670	59.9 (4600)	30.5 (2300)	22.5 (1725)	17.6 (1340)	22.4 (1718)	36.7	71.1	902
CBC; complete blood count, WBC; white blood cell, Hb; hemoglobin, Plt; platelet, MCV; mean corpuscular volume, Neu; neutrophil, Lym; lymphocyte, Ti^lo-Ti^up; lower and upper tolerance interval limits, d; day, mo; month, Ig; immunoglobulins,

Table 2

Summary of the clinical and laboratory results of patient 2
Period (age)	CBC					Lymphocyte subgroups						Immunoglobulins (Ig)
Period (age)	WBC X10³/mm³	Hb gr/dl	Plt X10³/mm³	MCV fl	Neu X10³/mm³	Lym X10³/mm³	CD3 % ( #)	CD4 % ( #)	CD8 % ( #)	CD 16 + 56 % ( #)	CD19 % ( #)	IgA (mg/dl)	IgM (mg/dl)	IgG (mg/dl)
Ti^lo-Ti^up (2–5 y)						1703–6738	1200–4706	458–2755	165–1878	205–1341	88-1393	26–296	71–235	604–1941
(2 y, in diagnosis)	12.84	10.6	51	86.2	6.35	4.94	58.5 (2880)	28.9 (1427)	26.6 (1314)	12.1 (597)	29.2 (1442)	112	71.7	1362
2nd month of treatment	17.39	11.8	296	85.3	6.66	7.21	63.5 (4578)	27.8 (2004)	30.4 (2191)	17.8 (1283)	18.8 (1355)	160	139	1600
6th month of treatment	10.89	12	360	72	3.67	5.87	59.3 (3480)	29.1 (1702)	29.9 (1755)	13.2 (774)	27.1 (1590)	103	80.9	1169
12th month of treatment	15.26	13	366	72.9	6.56	5.93	55.8 (3308)	23.6 (1399)	27.5 (1630)	16.0 (948)	28.1 (1666)	96.2	99.4	1072
CBC; complete blood count, WBC; white blood cell, Hb; hemoglobin, Plt; platelet, MCV; mean corpuscular volume, Neu; neutrophil, Lym; lymphocyte, Ti^lo-Ti^up; lower and upper tolerance interval limits, y; year, Ig; immunoglobulins.

G348R substitution does not alter SLC19A1 protein expression or stability

SLC19A1 is made up of 12 alpha-helices which are transmembrane domains [21]. The missense mutation (G348R) resides in 9th alpha helix (Fig. 1c). In the predicted model (UniProtKB- P41440), glycine in that position interacts with leucine 352, alanine 344 through hydrogen bonds (Fig. 1c). G348 has been conserved in several species from bats, humans to frogs (Fig. 1d) and has been replaced with alanine in Danio rerio, and serine in B. taurus. Compared with alanine and serine, which are similar in structure to glycine, arginine is bulkier, with more potential to impact the structure and/or function of SLC19A1 in the G348R variant (Fig. 1e). Antibody staining of SLC19A1 (which recognizes an epitope between 407 and 591 residues) has revealed that the protein is produced within the cells at comparable levels (Fig. 1f and 1g). The microscopical examination also revealed that mutant SLC19A1 can correctly shuttle to the plasma membrane (Fig. 1h). Importantly, when T cells are activated with mitogens such as anti-CD3/CD28 or PHA, mRNA expression of SLC19A1 and PCFT increased up to 10-fold in accord with the increased need for DNA synthesis (Fig. 1ı). These results collectively suggest that the protein expression and stability are unaffected by the G348R substitution and that proliferating T cells upregulate SLC19A1 expression.

SCL19A1 mutant T cells have proliferation defects in non-optimal folic acid concentrations and are resistant to MTX-induced cell death

To assess whether G48R substitution leads to a functional defect, lymphocyte proliferation assays were performed with different T cell mitogens. When the T cells were cultured in the complete medium containing 1 µg/mL (RPMI 1640 medium, no detectable differences in proliferation between healthy controls and the two patient’s lymphocytes were observed in response to activation with CD3 + CD28, CD3 + CD28 + IL-2, PHA (Fig. 2a, Fig. S2a). On the other hand, when the medium was diluted 1:1 with PBS which halved the folic acid concentration, (without reducing L-glutamine, antibiotics, fetal bovine serum amounts by adding them back) T cell proliferation was dramatically reduced, suggesting that the functional impact of the mutation may become visible in limiting folic acid conditions (Fig. 2b, Fig. S2b). Additionally, when folinic acid was added back into the regular medium which increased its levels 10-fold (10 µg/mL), T cells from healthy control proliferated more robustly compared with patient-derived T cells (Fig. 2c), collectively suggesting that the functional consequences of the mutation are observed under suboptimal and supraoptimal concentrations of folic/folinic acid.

MTX is an antifolate and blocks dihydrofolate reductase enzyme and is transported across cell membrane by SLC19A1 [14, 15, 17]. MTX reduces the activation of the immune system in autoimmune diseases and ceases cell proliferation in cancer and leads to apoptosis. Thus, to assess the functional defects in SLC19A1 with G348R substitution in a different assay, we further compared the import of MTX to cells by SLC19A1 indirectly by measuring the MTX-induced apoptosis (Fig. 3a and b). Indeed, when the two patient’s cells were exposed to increasing doses of MTX, compared with healthy controls, they were more resistant to apoptosis, suggesting an impaired transporter activity due to G348R substitution (Fig. 3a and b). Collectively, these data support that the G348R substitution impairs the function of SLC19A1.

Normal Treg number, NK cell cytotoxicity but altered cytokine production by T cells in SLC19A1 deficiency

Because the patient was initially suspected of HLH, and a heterozygous mutation in RAB27A was identified in patient 1, we compared the cytotoxic ability of patient-derived (Pt1 and Pt2) PBMCs to healthy controls to determine the cytotoxic potential of NK cells [22]. Comparable cytotoxicity of patients and healthy donors suggests normal NK cell function, and that the phenotype of both patients may be related to the mutation in SLC19A1 (Fig. 4a).

T and B cells are particularly sensitive to folate deficiency [7, 12, 14, 23]. To the best of our knowledge, the number of Treg cells has not yet been studied in patients with SLC19A1 defects. We found that the FOXP3 + Treg cell frequency among CD4 + T cells was comparable between SLC19A1-deficient patients and the age-matched controls (Fig. 4b). As shown in Fig. S3a, there was also no significant difference in the naive/memory ratio of CD4 + or CD4-CD3 + T cells between the patient's pre/post-treatment samples and age-matched controls. Examination of T helper-associated cytokines production by freshly isolated PBMCs after stimulation with PMA/Ionomycin in normal folic acid concentrations (1µg/mL) revealed that both patient 1 and patient 2 had a significantly increased IL-10 and GM-CSF percent and number compared to control (Fig. 4c top, Fig. S3b). In addition, no significant differences in IL-17A, IL-22, and IFN- γ production between the patients and controls were observed (Fig. 4c bottom). More recently, two independent studies demonstrated that SLC19A1 was critical in the transport of cyclic dinucleotides into the cytosol and that knockout of SLC19A1 lead to the reduced activation of cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway, ultimately leading to impaired production of antiviral interferons [24, 25]. To test whether patient-derived T cells had a bias towards the production of certain cytokines, we cultured microbead selected CD4 + T cells in reduced folic acid conditions (0.5µg/mL) in the presence of soluble anti-CD3/28(1µg/mL) for 4 days. Real-time qPCR analyses of several cytokines revealed reduced IFNA, IFNG, TNFA, and IL6 gene expression by CD4 + T cells of the patients compared with healthy controls (Fig. 4d). These data collectively suggest that helper T cell cytokine production may be skewed to the production of GM-CSF and that antiviral immunity may be compromised due to loss of SLC19A1 function.

Folate deficiency either due to insufficient dietary intake, or SLC46A1 deficiency (HFM) results in reduced systemic folate levels and leads to combined immunodeficiency which is classified under Table IIIb of IUIS 2019 classification [1, 3, 10, 11, 20]. Hematologic defects in SLC46A1 deficiency are mostly reversible when folate levels are restored by parenteral route [12]. On the other hand, a reduction in serum folate levels in SLC19A1 deficiency is not expected unless dietary intake is limited. Indeed, in Pt1 and Pt2, folate levels were normal at the time of diagnosis. Despite normal intestinal absorption of folates, SLC19A1 deficiency has potential to affect the generation and function of immune cells because cellular uptake will be impaired. Indeed, in the murine model, SLC19A1 deficiency is embryonic lethal, and only partially could be rescued by folate supplementation of the pregnant mice, even so hematopoiesis could not be rescued due to impaired cellular uptake [26]. The clinical history of both of our patients corroborates an immunodeficiency: LRTI and mucositis at the 1st week of birth, cytopenia (low IgG, reduced lymphocyte counts, borderline CD3 + T cells, reduced B cells), death of a sibling at 3.5 months due to infection, sores in the mouth in the Pt1 (40 days old at diagnosis); recurrent sores in the mouth, skin, and diaper area since 1 month old, rifts on the lip and tooth abnormality, erosive dermatitis in the scrotal area, growth and mental retardation, also a sibling death at 2 years of age (unknown cause) in the Pt2 (2 years old at diagnosis). The observation that the immunological symptoms of Pt1 (Table 1), sores, and general health of both patients greatly benefited from the folinic acid prescription supports that G348R substitution is a LOF mutation. Additionally, the neurological symptoms of Pt2, which are consistent with folic acid metabolism defect, provide additional support for the pathogenicity of this newly described SLC19A1 variant and underline the importance of folinic acid supplementation for the younger patient, Pt1.

The experimental evidence for the pathogenicity of the G348R substitution variant of SLC19A1 was provided by two different assays. Remarkably, mitogen-induced T cell proliferation experiments revealed a significant reduction in T cell proliferation only when the folic acid levels were reduced or very high, but not in normal media conditions. This observation suggests that the patients will be vulnerable to infection when folate intake is insufficient. This variant may present a problem during infections, especially when B and T cells need to undergo clonal expansion, and their folate demands are high. Indeed, our data show that during proliferation T cells increase SLC19A1 levels dramatically to accommodate that demand. Given that basal T and B cell numbers in Pt2 are within the reference range, frequent infections in those patients may be due to defective proliferation of T and B cells because of impaired cellular transport at limited/or normal folate concentrations in the environment. Folate analogs such as MTX are also transported by SLC19A1 [1, 10, 19, 24, 25]. Loss of SLC19A1 function mutations creates MTX-resistant cancer cells [17–19, 27]. Svaton et al. showed that gene-edited K562 cells carrying c.634_636delTTC (p.Phe212del) a mutation in SLC19A1, also became resistant to MTX [19]. The T cells of both patients in this study also demonstrated resistance to MTX-induced apoptosis further supporting that G348R is a LOF mutation.

While there are studies showing a decrease in T cell proliferation in folate deficiency, no detailed research has been conducted on CD4 + T cell subsets [7, 23, 28]. In the current study, we evaluated the CD4 + FOXP3 + Treg cell frequency of SLC19A1 deficient patients for the first time. Treg levels were normal in patients compared with healthy controls, although further functional studies are necessary to address potential functional defects, and if any, whether they are reversible. Analyses of cytokine profiles of T cells showed elevated GM-CSF+, IL-10 + T cell percentage, and increased absolute numbers of GM-CSF+, IL-10 + collectively pointing to a bias towards the production of GM-CSF in two patients. Folate deficient diet in mice was shown to reduce Th1-derived IFN-γ production by CD4 + T cells [28]. GM-CSF levels were not assessed in that study. It is yet unclear, how in vivo folate-deficient diet impacts type 3 immunity and particularly, Th17 cells, and IL-17A/F, IL-22, and GM-CSF cytokines. Further studies with murine conditional knockouts of SLC19A1 and SLC46A1 will shed more light on the nature of inflammation observed in oral mucosa and skin of SLC19A1 deficient patients. The final information revealed by our study is the reduced mRNA expression of IFNA, IFNG, TNFA, and IL6 by SLC19A1-deficient CD4 + T cells in culture, in the reduced folic acid environment. These data corroborate earlier findings that SLC19A1 may be important for antiviral immunity by transporting ligands of the cGAS-STING pathway and that these patients may have further disadvantages against viral infections due to curbed type I interferon response [24, 25].

In summary, in the current study, we identified a novel pathogenic mutation (c.1042G > A, p.G348R) in the SLC19A1 gene in two related children and provide the first experimental evidence that LOF mutations in SLC19A1 may present with symptoms of immunodeficiency, and that immunological defect of those patients could benefit from folinic acid supplementation.

Funding: This study was financially supported by Erciyes University BAP grant (TCD-2021-10863) to EÜ, and Turkish Academy of Science GEBIP and Science Academy BAGEP awards to AE.

Authorship Contributions: Conceptualization was performed by AE, EÜ. Methodology was performed by ŞE, YH, SB, KEB, CA, AE. Software was performed by AB. Investigation was performed by VG, ŞE, AÖ, EY, HP, TP, AE, EÜ. Validation was done by AB, MK, AE. Supervision was performed HC, AE, EÜ. Resources - Writing - original draft were written by VG, ŞE, YH, AE. Writing - review & editing were performed by VG, YH, SB, AÖ, EY, CA, MK, HC, HP, TP, AE, EÜ. Funding acquisition by AE, EÜ. All authors have read and approved the manuscript

Competing interests: The authors have no relevant financial or non-financial interests to disclose.

Consent to participate: Written informed consent was obtained from the parents.

Consent to publish: The authors affirm that human research participants provided informed consent for publication of the images in Figure 1.

Ethics approval: All experimental procedures were approved by Erciyes University institutional review board (#2021/17) and conducted according to regulations. Parents of the patients signed the informed consents for the immunological study and provided consent for the publication of data.

Availability of data and material: All the raw data are available upon reasonable request from the corresponding authors.

Code availability: Not applicable.

Shulpekova Y, Nechaev V, Kardasheva S, Sedova A, Kurbatova A, Bueverova E, et al. The Concept of Folic Acid in Health and Disease. Molecules. 2021;26:3731.
Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014;44:480–488.
Field MS, Kamynina E, Chon J, Stover PJ. Nuclear Folate Metabolism. Annu Rev Nutr. 2018;38:219–243.
Fernley RT, Iliades P, Macreadie I. A rapid assay for dihydropteroate synthase activity suitable for identification of inhibitors. Anal Biochem. 2007;360:227–234.
Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam. Horm. 2008;79:1–44
Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr. 2012;3:21–38.
Courtemanche C, Elson-Schwab I, Mashiyama ST, Kerry N, Ames BN. Folate Deficiency Inhibits the Proliferation of Primary Human CD8 + T Lymphocytes In Vitro. J Immunol. 2004;173:3186–3192.
Mikkelsen K, Apostolopoulos V. Vitamin B12, folic acid and the immune system. In: Mahmoudi M, Rezaei N, editors. Nutrition and Immunity. Switzerland: Springer; 2019. pp 103–114.
Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004;24:105–131.
Hou Z, Matherly LH. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175–204.
Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006;127:917–928.
Borzutzky A, Crompton B, Bergmann AK, Giliani S, Baxi S, Martin M, et al. Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clin Immunol. 2009;133:287–294.
Yang-Feng TL, Ma YY, Liang R, Prasad PD, Leibach FH, Ganapathy V. Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization. Biochem Biophys Res Commun. 1995;210:874–879.
Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: Biology and role in antifolate chemotherapy of cancer. Drug Metab Dispos. 2014;42:632–649.
Desmoulin SK, Hou Z, Gangjee A, Matherly LH. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol Ther. 2012;13:1355–1373.
Kishimoto K, Kobayashi R, Sano H, Suzuki D, Maruoka H, Yasuda K, et al. Impact of folate therapy on combined immunodeficiency secondary to hereditary folate malabsorption. Clin Immunol [Internet]. Elsevier Inc. 2014;153:17–22. http://dx.doi.org/10.1016/j.clim.2014.03.014
Kotnik BF, Jazbec J, Grabar PB, Rodriguez-Antona C, Dolzan V. Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach. Radiol Oncol. 201751:455–462.
Coppedè F, Stoccoro A, Tannorella P, Gallo R, Nicolì V, Migliore L. Association of Polymorphisms in Genes Involved in One-Carbon Metabolism with MTHFR Methylation Levels. Int J Mol Sci. 2019;20:3754.
Svaton M, Skvarova Kramarzova K, Kanderova V, Mancikova A, Smisek P, Jesina P, et al. A homozygous deletion in the SLC19A1 gene as a cause of folate-dependent recurrent megaloblastic anemia. Blood. 2020;135:2427–2431.
Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020;40:66–81.
Ferguson PL, Flintoff WF. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J Biol Chem. 1999;274:16269–78. doi: 10.1074/jbc.274.23.16269.
Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, et al. A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. J Immunol. 2016;196:2492–2503. doi: 10.4049/jimmunol.1501284.
Kinoshita M, Kayama H, Kusu T, Yamaguchi T, Kunisawa J, Kiyono H, et al. Dietary folic acid promotes survival of Foxp3 + regulatory T cells in the colon. J Immunol. 2012;189:2869–2878. doi: 10.4049/jimmunol.1200420.
Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, et al. SLC19A1 transports immunoreactive cyclic dinucleotides. Nature. 2019;573:434–438. doi: 10.1038/s41586-019-1553-0.
Ritchie C, Cordova AF, Hess GT, Bassik MC, Li L. SLC19A1 Is an Importer of the Immunotransmitter cGAMP. Mol Cell. 2019;75:372–381.e5. doi: 10.1016/j.molcel.2019.05.006.
Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, et al. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem. 2001;276:10224–10228. doi: 10.1074/jbc.c000905200.
Ifergan I, Jansen G, Assaraf YG. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. J Biol Chem. 2008;283:20687–20695. doi: 10.1074/jbc.M802812200.
Wu CH, Huang TC, Lin BF. Folate deficiency affects dendritic cell function and subsequent T helper cell differentiation. J Nutr Biochem. 2017;41:65–72. doi: 10.1016/j.jnutbio.2016.11.008.

There is NO conflict of interest to disclose. no

JGISupplementalMethods.docx
FigS1.tif
Fig. S1 Sanger Sequencing results for patients 1, and 2 and the father of patient 2
FigS2.tif
Fig. S2 G348R substitution in SLC19A1 reduces T cell proliferation in reduced folate concentrations: individual patients data a) PBMC’s from Pt1 and Pt2 were labeled with CFSE and activated with CD3/CD28, CD3/CD28/IL-2 or PHA for 4 days in complete medium, cell proliferation was quantified in top panel for Pt1, and bottom for Pt2. b) The same experiment was repeated in medium diluted with 2-fold with PBS to reduce folic acid by half. FBS, L-glutamine and antibiotics were kept constant by adding back. cell proliferation was quantified in top panel for Pt 1, and bottom for Pt2. () indicates P < 0.05, (**) P < 0.001, (****) P < 0.0001. The error bars show +/- SEM
FigS3.tif
Fig. S3 Naïve/memory ratio of CD3+ T cells and Cytokine production by TCRαβ+ T cells

Download PDF

Journal Publication

published 15 Dec, 2022

Read the published version in Genes & Immunity →

Editorial decision: revise
10 Oct, 2022
Review #2 received at journal
06 Oct, 2022
Reviewer #2 agreed at journal
20 Sep, 2022
Reviewer #1 agreed at journal
13 Aug, 2022
Reviewers invited by journal
25 Jul, 2022
Submission checks completed at journal
25 Jul, 2022
Editor assigned by journal
24 Jul, 2022
First submitted to journal
24 Jul, 2022

You are reading this latest preprint version

A Novel Loss of Function Variant of SLC19A1 Presented with Immunodeficiency and Benefited from Folinic Acid Treatment

Status:

Journal Publication

Version 2

Abstract

Figures

Introduction

Methods

Results

Case History of Patient 1

G348R substitution does not alter SLC19A1 protein expression or stability

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 2